Tenaya Therapeutics, Inc. TNYA
0.30 USD -0.01 (-2.74%)
Regular-session close
0.29 -0.01 -2.85%
After hours · Nov 19, 7:52 PM ET
0.28 Day range 0.3148
0.2985 52-week range 1.41
- YTD
- -58.08%
- 1 year
- -74.92%
News
defenseworld.net Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Now Rated “Moderate Buy” by Wall Street Brokerages Shares of Tenaya Therapeutics, Inc. (NASDAQ: TNYA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven brokerages that are currently covering the company, Marketbeat…
zacks.com Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.12 per share a year ago.benzinga.com Tenaya Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate, Sales $1.697M Beat $800.000K Estimate Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 percent. This is a 33.33 percent increase over losses of…
globenewswire.com Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program…
defenseworld.net Tenaya Therapeutics (NASDAQ:TNYA) and C4 Therapeutics (NASDAQ:CCCC) Financial Survey Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the…
seekingalpha.com Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
globenewswire.com Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden
globenewswire.com Tenaya Therapeutics to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
marketbeat.com Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief…
seekingalpha.com Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
globenewswire.com Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates…
globenewswire.com Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
globenewswire.com Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
globenewswire.com Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise
seekingalpha.com Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
seekingalpha.com Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
globenewswire.com Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater…
globenewswire.com Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
globenewswire.com Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver…
seekingalpha.com Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
